Gerald Reaven, MD, Professor, Active Emeritus, Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine
Research Description: Dr. Reaven has pioneered studies to evaluate the role of insulin resistance (IR) and secretion in human diseases for ~ 50 years. He helped developed the insulin suppression test (the first quantitative method to measure insulin-mediated glucose uptake), and used this technique to establish the importance of IR in the pathogenesis and clinical course of patients with type 2 diabetes. In addition, his group used these same approaches to gain new insights into human disease by developing and studying experimental models of diabetes, principally in rodents. In nondiabetic individuals, they demonstrated the role of IR and compensatory hyperinsulinemia in the development of: 1) coronary heart disease); 2) hypertriglyceridemia and a low high-density lipoprotein cholesterol concentration; 3) hyperuricemia; 4) enhanced postprandial lipemia and remnant lipoprotein accumulation; 5) salt sensitivity; 6) essential hypertension; and 7) increased sympathetic nervous system activity. These important achievements have been amply recognized and include the ADA Banting Award, and the Lilly, Koch and Pasarow Awards. These enduring achievements and continuing active work with trainees and colleagues at Stanford and around the world enable him to be an important contributor to the Stanford DRC mission. He is an active contributor to efforts by other Stanford colleagues to understand the genetic basis of IR and physiologically characterize risk genes. He also is active in studies to quantify the effect of statins on insulin resistance and insulin secretion.
Selected relevant publications (Stanford DRC Members in BOLD):
1. Kohli P, Knowles JW, Sarraju A, Waters DD, Reaven G. Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients. Am J Cardiol. 2016 Nov 1;118(9):1275-1281.
2. Knowles JW, Xie W, Zhang Z, Chennamsetty I, Assimes TL, … Abbasi F, Greenawalt DM, Lum P, Molony C, Lind L, Lindgren C, Raffel LJ, Tsao PS; RISC Consortium; EUGENE Study; GUARDIAN Consortium; SAPPHIRe Study,…Reaven G, Yang X, Hsiung CA, Groop L, Cordell HJ, Laakso M, Hao K, Ingelsson E, Frayling TM, Weedon MN, Walker M, Quertermous T. Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene. J Clin Invest. 2016 Jan;126(1):403.
3. Chennamsetty I, Coronado M, Contrepois K, Keller MP, Carcamo-Orive I, Sandin J, Fajardo G, Whittle AJ, Fathzadeh M, Snyder M, Reaven G, Attie AD, Bernstein D, Quertermous T, Knowles JW. Nat1 Deficiency Is Associated with Mitochondrial Dysfunction and Exercise Intolerance in Mice. Cell Rep. 2016 Oct 4;17(2):527-540.
4. Abbasi F, Kohli P, Reaven GM, Knowles JW. Hypertriglyceridemia: A simple approach to identify insulin resistance and enhanced cardio-metabolic risk in patients with prediabetes. Diabetes Res Clin Pract. 2016 Oct;120:156-61.
5. Kim SH, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, Tomasso V, Reaven G. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomized, placebo-controlled study. Diabetologia 2014; 57:455-462.